Axinn Advises McKesson on Joint Venture with HCA Healthcare
June 23, 2022
Axinn is representing McKesson Corporation (NYSE: MCK), a leading, diversified health care services company, in a joint venture combining McKesson’s US Oncology Research (USOR) and HCA Healthcare Inc.'s (NYSE: HCA) Sarah Cannon Research Institute (SCRI). Announced on June 23, 2022, the deal will create a fully integrated oncology research organization aimed at expanding clinical research, accelerating drug development and increasing availability and access to clinical trials for oncology providers and patients, including those in underserved communities. In the transaction with HCA, McKesson will also acquire Genospace, SCRI’s personalized medicine platform and an innovator in precision medicine and clinical trial matching. The Axinn antitrust team is led by partners Daniel Bitton and Jeny Maier, and assisted by associates Carol Liu, Danielle Irvine and Kelly McCluer.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
GCR Live: Law Leaders Europe 2025
Speaking Engagement
Antitrust
Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
Webinar
Antitrust
AHLA Annual Meeting 2025
Speaking Engagement
Antitrust
SABA North America Annual Conference 2025
Speaking Engagement
Antitrust
Patman Returns … and Retreats Again
Axinn Viewpoints
Antitrust
Axinn Successfully Reunites One of Its Pro Bono Clients, a Former Afghan Army Captain, with His Wife and Four Children
Pro Bono
The Texas v. Blackrock ESG Case: The FTC and DOJ Have Entered the Chat
Axinn Viewpoints
Volunteer Lawyers for the Arts – Champions of the Arts Awards and Gala 2025
Sponsorship
Antitrust
Washington Lawyers’ Committee for Civil Rights and Urban Affairs – 2025 Wiley A. Branton Awards Luncheon
Sponsorship
Antitrust
What's Happening in Germany and Portugal? Catching Up With International Enforcers at the 2025 Spring Meeting
Podcast
Antitrust